AU2006222500B2 - Use of a combination of Myxoma virus and rapamycin for therapeutic treatment - Google Patents

Use of a combination of Myxoma virus and rapamycin for therapeutic treatment Download PDF

Info

Publication number
AU2006222500B2
AU2006222500B2 AU2006222500A AU2006222500A AU2006222500B2 AU 2006222500 B2 AU2006222500 B2 AU 2006222500B2 AU 2006222500 A AU2006222500 A AU 2006222500A AU 2006222500 A AU2006222500 A AU 2006222500A AU 2006222500 B2 AU2006222500 B2 AU 2006222500B2
Authority
AU
Australia
Prior art keywords
cell
virus
cells
cancer
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006222500A
Other languages
English (en)
Other versions
AU2006222500A1 (en
Inventor
John Barrett
Grant Mcfadden
Marianne Stanford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Robarts Research Institute
Original Assignee
Robarts Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Research Institute filed Critical Robarts Research Institute
Publication of AU2006222500A1 publication Critical patent/AU2006222500A1/en
Application granted granted Critical
Publication of AU2006222500B2 publication Critical patent/AU2006222500B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006222500A 2005-03-07 2006-03-06 Use of a combination of Myxoma virus and rapamycin for therapeutic treatment Ceased AU2006222500B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
US60/658,816 2005-03-07
PCT/CA2006/000315 WO2006094385A1 (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Publications (2)

Publication Number Publication Date
AU2006222500A1 AU2006222500A1 (en) 2006-09-14
AU2006222500B2 true AU2006222500B2 (en) 2011-09-01

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006222500A Ceased AU2006222500B2 (en) 2005-03-07 2006-03-06 Use of a combination of Myxoma virus and rapamycin for therapeutic treatment

Country Status (14)

Country Link
US (5) US20090035276A1 (enExample)
EP (2) EP1863906A4 (enExample)
JP (2) JP2008531739A (enExample)
KR (1) KR101479093B1 (enExample)
CN (2) CN101137748B (enExample)
AU (1) AU2006222500B2 (enExample)
CA (1) CA2600675C (enExample)
DK (1) DK2388315T3 (enExample)
IL (2) IL185376A0 (enExample)
MX (1) MX2007010962A (enExample)
NZ (2) NZ560840A (enExample)
RU (1) RU2461630C2 (enExample)
UA (1) UA96412C2 (enExample)
WO (1) WO2006094385A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560840A (en) 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
KR20090014364A (ko) 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
DK2717887T3 (en) 2011-06-09 2018-04-09 Univ Florida Methods for treating or preventing graft-versus-host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
SG11202101291VA (en) * 2018-08-08 2021-03-30 Univ Arizona State Method for improved poxvirus yields
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2021046048A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
AU2020361625A1 (en) * 2019-10-10 2022-05-05 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
CA2378567A1 (en) * 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CN1754002B (zh) * 2002-08-12 2010-09-08 杰能斯有限公司 涉及痘病毒和癌的组合物及制备方法
EP1601376B1 (en) * 2003-03-07 2012-05-30 Robarts Research Institute Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
PT1615640E (pt) * 2003-04-22 2007-04-30 Wyeth Corp Combinações antineoplásticas
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2562904C (en) * 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
NZ560840A (en) 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Barrett et al. Abstract, 14th International Poxvirus and Iridovirus Conference, Lake Placid, NY, September 2002. *

Also Published As

Publication number Publication date
EP2388315A3 (en) 2012-05-02
JP2008531739A (ja) 2008-08-14
EP1863906A1 (en) 2007-12-12
RU2461630C2 (ru) 2012-09-20
EP1863906A4 (en) 2009-06-03
EP2388315B1 (en) 2014-05-21
US20140134134A1 (en) 2014-05-15
JP2012236860A (ja) 2012-12-06
RU2007137008A (ru) 2009-04-20
CA2600675C (en) 2015-12-15
WO2006094385A1 (en) 2006-09-14
CN102357104A (zh) 2012-02-22
EP2388315A2 (en) 2011-11-23
IL208070A0 (en) 2010-12-30
IL185376A0 (en) 2008-02-09
JP5674210B2 (ja) 2015-02-25
HK1163175A1 (en) 2012-09-07
CN101137748B (zh) 2011-12-14
KR101479093B1 (ko) 2015-01-26
KR20070110423A (ko) 2007-11-16
IL208070A (en) 2015-06-30
CA2600675A1 (en) 2006-09-14
US20130171106A1 (en) 2013-07-04
US20090035276A1 (en) 2009-02-05
CN101137748A (zh) 2008-03-05
NZ577283A (en) 2010-11-26
DK2388315T3 (da) 2014-08-25
CN102357104B (zh) 2016-01-27
AU2006222500A1 (en) 2006-09-14
US9987315B2 (en) 2018-06-05
UA96412C2 (ru) 2011-11-10
US20180256656A1 (en) 2018-09-13
US20110195050A1 (en) 2011-08-11
MX2007010962A (es) 2008-03-10
NZ560840A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
US9987315B2 (en) Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
US8227440B2 (en) Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment
CN100379453C (zh) 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途
HK1081099B (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired